Neurocrine Biosciences | NBIX - Le Chiffre D'Affaires De Vente





Ventes Changement Date
AbbVie USD 15B 1.62B 2026-03
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
ALKERMES USD 392.91M 8.41M 2026-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Amgen USD 8.62B 1.28B 2026-03
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Cytokinetics USD 19.35M 1.59M 2026-03
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Exelixis USD 610.8M 12.14M 2026-03
Gilead Sciences USD 7B 930M 2026-03
Halozyme Therapeutics USD 377M 74.76M 2026-03
Incyte USD 1.27B 240M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Prothena USD 51.08M 51.06M 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Repligen USD 194M 3.91M 2026-03
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Teva Pharmaceutical Industries USD 11.77B 2.86B 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Vertex Pharmaceuticals USD 2.99B 200M 2026-03
Xoma USD 25K 5M 2024-09